285 related articles for article (PubMed ID: 12446423)
41. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
42. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
43. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
44. Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia.
Sawada A; Sakata N; Kishimoto T; Higuchi B; Koyama M; Kondo O; Sato E; Okamura T; Yasui M; Inoue M; Yoshioka A; Kawa K
Leuk Res; 2009 Dec; 33(12):1710-3. PubMed ID: 19596431
[TBL] [Abstract][Full Text] [Related]
45. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
46. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
47. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
48. Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Rettinger E; Merker M; Salzmann-Manrique E; Kreyenberg H; Krenn T; Dürken M; Faber J; Huenecke S; Cappel C; Bremm M; Willasch A; Bakhtiar S; Jarisch A; Soerensen J; Klingebiel T; Bader P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):87-95. PubMed ID: 27742575
[TBL] [Abstract][Full Text] [Related]
49. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.
Marshall GM; Haber M; Kwan E; Zhu L; Ferrara D; Xue C; Brisco MJ; Sykes PJ; Morley A; Webster B; Dalla Pozza L; Waters K; Norris MD
J Clin Oncol; 2003 Feb; 21(4):704-9. PubMed ID: 12586809
[TBL] [Abstract][Full Text] [Related]
50. New approaches to acute lymphoblastic leukemia in adults: where do we go?
Hoelzer D; Gökbuget N
Semin Oncol; 2000 Oct; 27(5):540-59. PubMed ID: 11049022
[TBL] [Abstract][Full Text] [Related]
51. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
52. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
53. Risk-adapted treatment according to minimal residual disease in adult ALL.
Gökbuget N; Kneba M; Raff T; Bruggemann M; Scheuring U; Reutzel R; Hoelzer D
Best Pract Res Clin Haematol; 2002 Dec; 15(4):639-52. PubMed ID: 12617868
[TBL] [Abstract][Full Text] [Related]
54. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
55. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
57. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
58. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
59. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
Chen X; Wood BL
Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
[TBL] [Abstract][Full Text] [Related]
60. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
Moppett J; Burke GA; Steward CG; Oakhill A; Goulden NJ
J Clin Pathol; 2003 Apr; 56(4):249-53. PubMed ID: 12663634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]